We retrospectively analyzed patients with metastatic STS treated with antiangiogenic agents plus PD-1 inhibitors in Henan Cancer Hospital, the Fifth Affiliated Hospital of Zhengzhou University, and Henan Provincial People’s Hospital between June 2019 and May 2022. This study complied with the principles of Helsinki, met the requirements of the ethics committee and was approved by the ethics committees of each institute. All participants provided written informed consent before treatment.
Patients were included according to the main criteria: 1. Age 18 to 70; 2. The performance status of Eastern Tumor Cooperative Group (ECOG) is 0-2; 3. The pathological diagnosis included ASPS, UPS, synovium, LMS, epithelioid sarcoma (ES), fibrosarcoma, etc. 4. At least one measure based on the Response Evaluation Criteria for Solid Tumors (RECIST) 1.1; 5. Complete medical history and follow-up records; 6. Not eligible for or refusing first-line chemotherapy; and 7. Progressive disease within 6 months before combination treatment. Patients were excluded if they presented contraindications of antiangiogenic agents and/or PD-1 inhibitors including coagulation dysfunction, active asthma, etc.
Patients were included according to the main criteria: 1. Age 18 to 70; 2. The performance status of Eastern Tumor Cooperative Group (ECOG) is 0-2; 3. The pathological diagnosis included ASPS, UPS, synovium, LMS, epithelioid sarcoma (ES), fibrosarcoma, etc. 4. At least one measure based on the Response Evaluation Criteria for Solid Tumors (RECIST) 1.1; 5. Complete medical history and follow-up records; 6. Not eligible for or refusing first-line chemotherapy; and 7. Progressive disease within 6 months before combination treatment. Patients were excluded if they presented contraindications of antiangiogenic agents and/or PD-1 inhibitors including coagulation dysfunction, active asthma, etc.
Free full text: Click here
